Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
Event:
Heart Failure 2025
Topic:
Pharmacotherapy
Session:
ePosters in chronic heart failure - pharmacotherapy (2)
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
